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ABSTRACT
Mycoprotein is an alternative, nutritious protein source with a meat-like texture made from
Fusarium venenatum, a naturally occurring fungus. Its unique method of production yields a
significantly reduced carbon and water footprint relative to beef and chicken. Mycoprotein, sold
as Quorn, is consumed in 17 countries, including the United States. In line with current dietary
guidelines, mycoprotein is high in protein and fiber, and low in fat, cholesterol, sodium, and
sugar. Mycoprotein may help maintain healthy blood cholesterol levels, promote muscle
synthesis, control glucose and insulin levels, and increase satiety. It is possible that some
susceptible consumers will become sensitized, and subsequently develop a specific allergy.
However, a systematic evidence review indicates that incidence of allergic reactions remains
exceptionally low. Mycoprotein’s nutritional, health, and environmental benefits affirms its role in
a healthful diet. Future research that focuses on the long-term clinical benefits of consuming a
diet containing mycoprotein is warranted. Curr Dev Nutr 2019;3:nzz021.
The objectives of this symposium were to describe the source, processing, and environmental
impact of mycoprotein; describe mycoprotein’s key nutritional attributes for human health; and
examine areas of emerging mycoprotein research related to worldwide health issues.
Dr Tim Finnigan, Chief Scientific Advisor for Marlow Foods (Stokesley, UK) described
mycoprotein’s discovery, processing, approval as a food ingredient, introduction into the food
supply, and its environmental footprint. He explained that >50 years ago, the “green revolution”
inspired British scientists, led by Lord Rank, to find a new, sustainable protein source that
could convert plentiful starch into less plentiful protein. He described how scientists collected
and tested >3000 soil organisms from around the world until they discovered that Fusarium
venenatum, a filamentous microfungus found originally in a field in Buckinghamshire, UK, made
this conversion (1). It took 20 years of research and development to produce the mycoprotein, via
the continuous fermentation of F. venenatum followed by steaming, chilling, and freezing of the
RNA-reduced biomass (2). This process results in a high-protein and high-fiber food with a high
degree of fibrosity through fiber assembly. When examined under a microscope mycoprotein that
has been prepared in this way has a texture similar to that of chicken breast (3). By dry weight,
mycoprotein is typically 45% protein and 25% fiber (1). Table 1 provides mycoprotein’s nutrient
content in its food ingredient form.
Eventually, mycoprotein was produced in sufficient quantities to be tested for use as a
commercial food ingredient. In 1983, after a 10-y evaluation, the UK Ministry of Agriculture,
Fisheries and Food approved mycoprotein for food use. Two years later, a savory pie became
the first mycoprotein-containing retail product sold in the UK under the brand name Quorn
(Marlow Foods). In 2002, the US FDA designated mycoprotein as “Generally Recognized as
Safe” and 7 Quorn products were introduced into the US food supply (4). Currently, Quorn is
sold in 17 countries as an ingredient in frozen or refrigerated food products with an estimated
5 billion servings consumed worldwide since launch. Since a small amount of egg albumin is
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added as a binder at the end of processing, Quorn foods cannot be
classed as vegan. However, recent breakthroughs in food technology
are now allowing an increasing proportion of the Quorn portfolio to
be sold without egg and these have received approval from the Vegan
Society. This trend is set to continue. In addition, recent investigations
into technologies such as high-pressure homogenization now offer the
possibility that mycoprotein can be used to create new vegan formats,
flavors, and uses, notably applications in the growing nondairymilk and
desserts category.
Production ofmycoprotein through fermentation provides a distinct
and relatively benign environmental footprint. These environmental
impacts have been quantified through the use of techniques such as
lifecycle analysis that conform to international standards and whose
conclusions are independently audited and certified by the Carbon
Trust (5). Comparison of Quorn grounds with beef, for example, show
≥10 times less embedded carbon, land, and water use (6). In addition,
because mycoprotein is grown with the carbohydrate fraction of crops
as the fermentation substrate, the process can be considered to give rise
to an overall net gain in protein. This is because the original protein
from the crops is not used in the fermentation of mycoprotein and
is thus conserved. This is unlike many other food protein production
systems, most notably animal protein, which result in a net decrease
in protein because of their inherent inefficiencies. Thus, as we look at
the increasing difficulties of assuring a global sustainable food future,
mycoprotein fermentation technology offers an important new tool
with which to meet this challenge.
Dr Benjamin Wall, Senior Lecturer in Nutritional Physiology,
Department of Sport and Health Sciences, University of Exeter, UK,
explained the potential role of mycoprotein in supporting skeletal
muscle maintenance and reconditioning. Although skeletal muscle can
be increased through conditioning, he noted that the worldwide aging
population is facing sarcopenia, the age-related loss of muscle mass. By
80 y of age, body composition changes result in an almost 50% loss of
muscle mass (from 48% to 25%) and an 84% increase in body fat (from
19% to 35%) (7).
Dr Wall described how stable isotopes are used to measure in vivo
rates of muscle protein synthesis. Using this method, nutrition coupled
with exercise was demonstrated to have a synergistic anabolic effect
on muscle protein synthesis rates in healthy young men, facilitating
reconditioning (i.e., adaptation) (8). In line with this, protein intake
above the RDAwas demonstrated to augment the adaptation to training
(9,10).
With aging, however, muscle protein metabolism changes. Anabolic
resistance to dietary protein in older adults appears to be a key factor
underlying sarcopenia (11). Additionally, older adults require a larger
amount of protein per meal to optimize muscle protein synthesis rates
(12). Specifically, to offset sarcopenia, adults aged 66–87 and >87 y
may require a daily protein intake of 1.2 and 1.6 g/kg body weight
(13,14), respectively, which is a 50% and 100% increase compared with
the recommended intake of 0.8 g/kg body weight for younger adults.
Considering the global demands for protein in a rapidly increasing
aging population, it is important to determine sustainable ways to meet
future protein needs.
Assessment of in vivo muscle protein synthesis rates after consump-
tion of meat, eggs, milk (casein and whey), free amino acids, soy,
and other plant-based protein sources indicates that the postprandial
anabolic potential of a particular dietary protein is primarily a function
of its amino acid composition. Other factors include the postprandial
insulin response, digestion and absorption kinetics, and amino acid
bioavailability (15,16).
Mycoprotein is rich in essential amino acids (EAAs). Its EAA
composition as a percentage of total protein is 41%, similar to spirulina.
This value is higher than most other commonly consumed plant-
based proteins. Although almost all animal sources of protein have a
higher percentage of EAA relative to total protein (≤52% for whey),
mycoprotein’s composition compares favorably with human muscle (at
45%) (17). As a sustainable, plant-based protein, mycoprotein may play
an important role in meeting the protein needs of an aging population.
To assess the effect of mycoprotein ingestion on plasma EAA
and BCAA concentrations, a randomized, single-blind, crossover,
dose-response study in 12 healthy young males was conducted (18).
Postprandial plasma EAA and BCAA concentrations were assessed in
the fasting state, and at regular intervals for 4 h after subjects consumed
either 20 g milk protein, a “mass-matched” bolus of mycoprotein,
a protein-matched bolus of mycoprotein, or 60 or 80 g boluses of
mycoprotein. Results indicate a significant effect of time, and time ×
treatment. Mycoprotein ingestion resulted in slower butmore sustained
plasma EAA and BCAA concentrations compared with milk when
protein matched. Increasing the dose of mycoprotein amplified these
effects, with some evidence of a plateau at 60–80 g (18).
Dr Wall noted that ongoing research supports the synergistic effect
of mycoprotein plus exercise on muscle protein synthesis. His future
research will focus on mycoprotein’s ability to stimulate muscle protein
synthesis rates in older adults; differences in muscle protein synthesis
responses between mycoprotein and animal-derived protein sources in
rested and exercisedmuscle in healthy young athletes; andmycoprotein
as a component of diets that support training adaptations in young
athletes or muscle reconditioning in active older adults.
Dr Peter Wilde, Professor in the Food Innovation & Health
Programme, Quadram Institute Bioscience, Norwich, UK, provided
insights into the role of the food matrix structure on digestibility and
bioavailability. Structure is a critical component of food. It not only
affects food quality (e.g., taste, texture and shelf life), but it also affects
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digestion and absorption of nutrients that may have health benefits
(19,20). Controlling or delaying digestion by consuming a food with
resistant starch, for example, can result in a reduced glycemic response,
reduced appetite, and change in colonic microbiota (21). These changes
may decrease the risk for type 2 diabetes.
Dietary fiber, found in cell walls, remains undigested in the
small intestine. Fiber can encapsulate and control the release and
absorption of nutrients in plant-based foods (20,22). The dietary fiber in
mycoprotein is naturally occurring and is comprised of approximately
one-third chitin (N-acetylglucosamine) and two-thirds β-glucan (1,3-
glucan and 1,6-glucan) (23).
Ongoing research aims to determine potential mechanisms un-
derpinning nutrient bioavailability from mycoprotein by examining
cell wall structural changes during processing and digestion. To study
the effect of structure, the mycoprotein particle size was decreased
from 140 to <20 μm through incubation, homogenization, sonication,
or grinding with glass beads. Smaller particles released the largest
percentage of protein (30%). However, to reduce the particle size,
intensive treatments such as sonication and grinding were required
to disrupt cells and release protein, indicating that mycoprotein’s
cell walls are effective at encapsulating proteins and are resistant to
disruption. In vitro digestion studies further reveal a total protein
release of 51% from the mycoprotein structure, primarily occurring
in the small intestine. However, fluorescence microscopy indicates
that even after postintestinal digestion, cell walls appear to be intact
and unchanged. Therefore, a simple in vitro digestion results in a
greater release of protein than intensive physical treatments such as
ultrasound. This suggests that the high protein bioavailability observed
by Dr Wall’s group is due to the action of the digestive conditions on
the mycoprotein cell wall properties. It is thus possible that digestion
instigates a significant change in the porosity of mycoprotein’s cell
walls, enabling either protein release or access by the digestive enzymes.
Further research is needed to determine the fundamental nature of these
changes, and how and why they lead to the high protein bioavailability.
Dr Francis Stephens, Associate Professor of Nutritional Physiology,
University of Exeter, UK, discussed the positive effects of mycoprotein
consumption on glycemia, insulinemia, lipidemia, and short-term
energy intake. He described one of the early studies that reported
lean subjects who consumed a 250-mL milkshake containing 17 g
mycoprotein had a 13% reduction in glycemia 1 h postingestion (24).
He then discussed a later randomized trial that was conducted in
overweight and obese subjects who consumed low- (44 g), medium-
(88 g) or high- (132 g) protein meals containing isocaloric amounts of
mycoprotein or chicken (24). The carbohydrate and fat content of the
meals were similar, but fiber was higher in all mycoprotein compared
to matched chicken meals. Results indicated that mycoprotein meals
had no effect on glycemic response, but they elicited a reduced insulin
response at every level compared with chicken. Energy intake at an ad
libitum lunch following test meals was lower only at the highest level of
mycoprotein (25).
Stephens noted that ongoing research by Coelho and colleagues
at the University of Exeter is examining the metabolic effects of a
1-wk high-mycoprotein diet. Pilot study results suggest no effect of
mycoprotein on blood glucose or serum insulin concentrations during
an oral glucose tolerance test. The NMR metabolomics biomarker
approach revealed only a nonsignificant (P = 0.06) decrease in the
plasma glucose response, whereas a significant robust decrease in
plasma cholesterol, predominantly in the smaller lipoprotein particles,
was seen. These results support earlier findings that showed cholesterol
reductions following mycoprotein consumption over 3- and 8-wk
periods (26,27).
The cholesterol-lowering effects of mycoprotein appear to be due to
its high fiber content, coupled with its unique composition. Chitin and
β-glucans create a fibrous, 88% insoluble matrix that may be a factor in
delaying BCAA or glucose absorption, and impairing cholesterol or bile
absorption. Further, bacterial metabolism of fiber in the gut may result
in a greater production of SCFAs that may affect cholesterol synthesis
or lipolysis.
Mycoprotein appears an appropriate dietary component for
metabolic health. Studies that use more robust measures such as the
euglycemic hyperinsulinemic clamp are needed to confirm results
regarding improved insulin sensitivity. Continued use of metabolomics
biomarker approaches and long-term feeding studies are warranted.
Dr Steve Taylor, Food Allergy Research and Resource Program,
University of Nebraska–Lincoln, NE, discussed the initial approval of
mycoprotein as a food ingredient in the United States as well as issues
relating to its safety in the food supply. He explained that Miller and
Dwyer (28) reviewed the basis for “Generally Recognized as Safe”
approval in the United States, and that following a review of all available
information in 1998, the Expert Panel concluded that, to a reasonable
scientific certainty, “Mycoprotein is a safe and suitable ingredient for use
in food as a source of protein in the diet” (28).
Taylor noted that the main issue relating to food safety relates to
allergenicity, and reminded the audience that ingestion of any novel
dietary protein, including mycoprotein, may elicit an allergic reaction.
He explained how susceptible consumers will become sensitized and
develop mycoprotein-specific IgE antibodies. Since US approval in
2002, 5 individual case reports of mycoprotein-specific allergy (29–33)
and 1 case of food protein–induced enterocolitis syndrome—a type of
food allergy affecting the gastrointestinal (GI) tract—have appeared in
the clinical literature (34). The best-investigated case reported that a 41-
y-old male with an allergic reaction to mycoprotein had a positive skin
test and serum IgE to Fusarium sp. (30)
In 2015, the York Health Economics Consortium conducted a
systematic review of allergic reactions to mycoprotein. Among 30
experimental studies, investigators confirmed only 2 reactions. The
Consortium concluded: “An assessment of the published and unpub-
lished evidence indicates that reported intolerance reactions to Quorn
are very low relative to common allergenic foodstuffs. Adverse reactions
of any kind to Quorn are rare and for the vast majority of individuals,
Quorn represents a safe foodstuff.…Rare cases of true allergy toQuorn
do occur, as for many other common foods” (35).
Taylor explained how Marlow Foods has tracked worldwide con-
sumer complaints since mycoprotein entered the UK marketplace in
1985. Examination of all reported adverse reaction complaints, without
an attempt to differentiate between genuine and coincidental, indicates
that the incidence of worldwide adverse reactions reported to the
company over>30 y remains exceptionally low. Taylor conducted an in-
depth analysis of the Marlow Foods database of reported illnesses (RIs)
over the most recent 15-y period (2003–2017). RIs were characterized
as either GI intolerance or possible IgE-mediated, true allergy, with
symptoms beyond GI. The possible frequency of both categories of RI
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was determined as a function of yearly packages of Quorn sold and of
servings potentially consumed. Because the analysis was based on self-
reported data, and the assumption was that any RI was attributed to
mycoprotein, results likely overestimate the true frequency and should
be considered a worst-case scenario.
Over the 15-y period, the frequency of RIs per packages soldwas 1RI
per 683,665 packages or 1 RI per 1.85 million servings. The frequency
of possible IgE-mediated reactions (true allergy) was 1 per 8.99 million
packages or 1 per 24.3 million servings. Over this 15-y period, the
database recorded a total of 2327 RIs, of which 177 are reports where
symptoms are “allergic” in their description. Forty-two of the total RI
reports suggest some formofmedical treatmentwas sought, a frequency
of 1 in 37.9 million packages sold. Examination of these self-reported
data, both real and extrapolated, indicates that although mycoprotein
may be allergenic, the rate of allergic reactions is extremely low—1 in
9 million packages.
Novel sources of dietary protein will always provoke allergic
reactions in some consumers. With the surge of novel protein sources
(e.g., pea, lupin, insects, and hemp) entering the US marketplace, and
the increased intake of existing protein sources (e.g., casein, whey, and
soy), it is likely that rates of allergic reactions to novel protein sources
will increase. Although the rate of such reactions compared with those
elicited by mycoprotein is unknown, it is well known that allergies
to milk, soy, legumes, and crustacean shellfish (which are related to
insects) are common.
The Marlow Foods database indicates that 92% of RIs are only
associated with GI symptoms. An Expert Panel comprised of scientists
from the United States, the United Kingdom, and Australia was
convened in 2011 to review adverse reactions and possible causal
mechanisms. The Panel concluded that GI symptoms were likely due
to mycoprotein’s high fiber content. They hypothesized that in certain
individuals under certain conditions, consuming mycoprotein could
speed up the normal transit time of foods from the small intestine
to the large intestine. This could, in turn, cause rapid fermentation of
mycoprotein fiber in the large intestine, causing GI distress symptoms.
Predisposing factors include usual dietary fiber intake, imbalance of
GI bacteria, or ≥1 manifestations of irritable bowel syndrome. The
Panel concluded that mycoprotein is safe and suitable for consumers,
including the elderly and those who might benefit from its fiber and
protein content (36).
The Center for Science in the Public Interest (CSPI) has collected
anecdotal reports on adverse reactions (both GI complaints and allergic
reactions) tomycoprotein through its website since 2002. Between 2002
and 2014, the number of incidents occurring in the United Kingdom
that were reported to CSPI (1095) and Marlow Foods (11181) was
comparable. During this time, there were twice as many incidents
occurring in the United States reported to CSPI (683) as compared with
Marlow Foods (356), but fewer worldwide incidents (229 compared
with 308, CSPI compared with Marlow, respectively). CSPI claims that
mycoprotein is unsafe, even though they fail to present the denominator
that would allow for an estimate of the frequency of unsafe reactions.
CSPI also indicates that 63% of respondents had adverse reactions on
their first exposure to mycoprotein. Because individuals have to be
sensitized first, it is more likely that these reactions were GI in nature,
and unlikely to be allergic reactions. Additionally, self-reported data
should be treated with caution.
Novel food sources of protein introduced into the US food
supply (such as lupine, peas, canola protein isolate, insects, wheat
protein isolate, and mycoprotein) can become allergenic. Predictors of
allergenic potential include knowledge that the food source is allergenic
when consumed in limited quantities (e.g., cottonseed protein) or that it
is allergenic in another country where it is more commonly consumed
(e.g., buckwheat among Japanese and Koreans). Other predictors
includewhether the food is genetically related to known allergenic foods
(e.g., canola protein is very closely related to mustard) or if the food
contains a potentially cross-reactive protein (e.g., insects and crustacean
shellfish). Whether the protein is readily digestible is also a predictor.
From an allergy perspective, mycoprotein may be among the safest
novel protein sources on the market.
In conclusion, this symposium confirmed that mycoprotein is a
nutritious, sustainable protein source in line with current dietary
guidelines. Research suggests that mycoprotein may help maintain
healthy blood cholesterol levels and promote muscle synthesis, control
blood glucose and insulin, and increase satiety. As a protein, it is
possible that some susceptible consumers will become sensitized, and
subsequently develop a specific allergy. However, a systematic review
of the evidence indicates that the incidence of allergic reactions to
mycoprotein remains exceptionally low. In the opinion of the speakers,
mycoprotein’s nutritional, health, and environmental benefits affirm its
safety and role in a healthful diet. Future research that focuses on long-
term clinical benefits of consuming a diet containing mycoprotein is
warranted.
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